Vor Biopharma (NASDAQ:VOR) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded Vor Biopharma from “Hold” to “Sell,” contrasting with an overall MarketBeat analyst consensus of “Moderate Buy” and an average price target of $38.
• Vor Biopharma shares opened at $19.68 after declining 5.9%; the company reported a quarterly loss of $1.45 per share, missing the consensus estimate of a $0.81 loss.
• Institutional investors and hedge funds own 97.29% of the stock, with several firms recently increasing holdings or initiating new positions.

Vor Biopharma (NASDAQ:VOR - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. Citigroup raised shares of Vor Biopharma to a "strong-buy" rating in a research note on Thursday, October 15th. William Blair assumed coverage on Vor Biopharma in a research report on Wednesday, October 21st. They set an "outperform" rating on the stock. Weiss Ratings raised Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a report on Monday, September 14th. Finally, Wedbush raised their price objective on Vor Biopharma from $18.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Vor Biopharma has an average rating of "Moderate Buy" and an average target price of $38.00.

Vor Biopharma Trading Down 5.9%

Vor Biopharma stock opened at $19.68 on Friday. Vor Biopharma has a fifty-two week low of $6.50 and a fifty-two week high of $26.76. The firm has a 50 day moving average price of $20.75 and a 200 day moving average price of $17.33.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its earnings results on Friday, October 30th. The company reported ($1.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.64). As a group, equities research analysts anticipate that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of VOR. Bank of America Corp DE raised its position in Vor Biopharma by 28,408.1% during the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company's stock worth $2,014,000 after buying an additional 112,496 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma in the first quarter valued at about $2,298,000. Braidwell LP boosted its holdings in shares of Vor Biopharma by 22.8% in the second quarter. Braidwell LP now owns 573,104 shares of the company's stock valued at $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Vor Biopharma in the second quarter valued at about $499,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma during the second quarter worth about $1,799,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor's platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.